TY - JOUR
T1 - Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes.
AU - Ahrén, Bo
AU - Schweizer, Anja
AU - Dejager, Sylvie
AU - Dunning, Beth E
AU - Nilsson, Peter
AU - Persson, Margaretha
AU - Foley, James E
PY - 2009
Y1 - 2009
N2 - Context: Dipeptidyl peptidase-4 (DPP-4) inhibitors act by increasing plasma levels of glucagon-like peptide-1 (GLP-1) and suppressing excessive glucagon secretion in patients with type 2 diabetes (T2DM). However, their effects on the glucagon response to hypoglycemia are not established. Objective: Assess effects of the DPP-4 inhibitor vildagliptin on alpha-cell response to hyper- and hypoglycemia. Design: Single-center, randomized, double-blind, placebo-controlled, two-period crossover study of 28-d treatment, with a 4-wk between-period washout Setting: Participants received study drug as outpatients. Patients: Drug-naïve patients with T2DM and baseline HbA1c </=7.5% Intervention: Vildagliptin (100 mg qd) or placebo Primary Outcome Measure(s): 1) Change in plasma glucagon levels during hypoglycemic (2.5 mM glucose) clamp. 2) Incremental (Delta) glucagon area under the concentration-time curve from time 0 to 60 min (AUC0-60min) during standard meal test. Before the study, it was hypothesized that vildagliptin would suppress glucagon secretion during meal tests and enhance the glucagon response to hypoglycemia. Results: The mean change in glucagon during hypoglycemic clamp was 46.7+/-6.9 ng/liter with vildagliptin treatment and 33.9+/-6.7 ng/liter with placebo; the between-treatment difference was 12.8+/-7.0 ng/liter (P=0.039), representing a 38% increase with vildagliptin. In contrast, the mean glucagon DeltaAUC0-60min during meal test with vildagliptin was 512+/-163 ng/liter.min vs 861+/-130 ng/liter.min with placebo; the between-treatment difference was -349+/-158 ng/liter.min (P=0.019), representing a 41% decrease with vildagliptin. Conclusions: Vildagliptin enhances alpha-cell responsiveness to both the suppressive effects of hyperglycemia and the stimulatory effects of hypoglycemia. These effects likely contribute to the efficacy of vildagliptin to improve glycemic control as well as to its low hypoglycemic potential.
AB - Context: Dipeptidyl peptidase-4 (DPP-4) inhibitors act by increasing plasma levels of glucagon-like peptide-1 (GLP-1) and suppressing excessive glucagon secretion in patients with type 2 diabetes (T2DM). However, their effects on the glucagon response to hypoglycemia are not established. Objective: Assess effects of the DPP-4 inhibitor vildagliptin on alpha-cell response to hyper- and hypoglycemia. Design: Single-center, randomized, double-blind, placebo-controlled, two-period crossover study of 28-d treatment, with a 4-wk between-period washout Setting: Participants received study drug as outpatients. Patients: Drug-naïve patients with T2DM and baseline HbA1c </=7.5% Intervention: Vildagliptin (100 mg qd) or placebo Primary Outcome Measure(s): 1) Change in plasma glucagon levels during hypoglycemic (2.5 mM glucose) clamp. 2) Incremental (Delta) glucagon area under the concentration-time curve from time 0 to 60 min (AUC0-60min) during standard meal test. Before the study, it was hypothesized that vildagliptin would suppress glucagon secretion during meal tests and enhance the glucagon response to hypoglycemia. Results: The mean change in glucagon during hypoglycemic clamp was 46.7+/-6.9 ng/liter with vildagliptin treatment and 33.9+/-6.7 ng/liter with placebo; the between-treatment difference was 12.8+/-7.0 ng/liter (P=0.039), representing a 38% increase with vildagliptin. In contrast, the mean glucagon DeltaAUC0-60min during meal test with vildagliptin was 512+/-163 ng/liter.min vs 861+/-130 ng/liter.min with placebo; the between-treatment difference was -349+/-158 ng/liter.min (P=0.019), representing a 41% decrease with vildagliptin. Conclusions: Vildagliptin enhances alpha-cell responsiveness to both the suppressive effects of hyperglycemia and the stimulatory effects of hypoglycemia. These effects likely contribute to the efficacy of vildagliptin to improve glycemic control as well as to its low hypoglycemic potential.
U2 - 10.1210/jc.2008-2152
DO - 10.1210/jc.2008-2152
M3 - Article
SN - 1945-7197
VL - 94
SP - 1236
EP - 1243
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
ER -
